Patents Assigned to Longhorn Vaccines & Diagnostics LLC
-
Patent number: 11041216Abstract: The invention is directed to compositions and methods for rapidly detecting, amplifying, and quantitating one or more pathogen-specific nucleic acids in a biological sample, and in particular, samples obtained from patients with sepsis. The invention also provides diagnostic kits containing specific amplification primers, and labeled detection probes that specifically bind to the amplification products obtained therefrom. The invention is also directed to detecting the quantity or ratio of genomic sequences and mRNA sequences of an individual suspected of being infected with an infectious agent over time to assess the progress of the infection over time. Also disclosed are compositions and methods for the isolation and characterization of nucleic acids that are specific to one or more pathogens, such as, for example, Influenza virus, Mycobacterium tuberculosis, Plasmodium, and/or HIV from a wide variety of samples including those of biological, environmental, clinical and/or veterinary origin.Type: GrantFiled: November 25, 2016Date of Patent: June 22, 2021Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Jeffrey D. Fischer, Luke T. Daum, Gerald W. Fischer
-
Publication number: 20210115498Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.Type: ApplicationFiled: December 21, 2020Publication date: April 22, 2021Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Publication number: 20210079450Abstract: The invention is directed to compositions and methods for collecting, transporting, and storing, without refrigeration, biological materials, which may comprise samples of biological, clinical, forensic, and/or environmental origin. These compositions preserve the viability of the collected organisms and/or the RNA/DNA and proteins in the sample composition mixture and permit the long-term storage of samples. Compositions are compatible with subsequent manipulation of the sample, including propagation and culture of the collected microorganisms, or isolation, purification, detection, and characterization of proteins, nucleic acids, and other macromolecules.Type: ApplicationFiled: September 2, 2020Publication date: March 18, 2021Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Luke T. Daum, Gerald W. Fischer
-
Patent number: 10870878Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.Type: GrantFiled: June 19, 2017Date of Patent: December 22, 2020Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Patent number: 10787504Abstract: The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.Type: GrantFiled: August 2, 2019Date of Patent: September 29, 2020Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum, Richard F. Schuman, Clara J. Sei
-
Publication number: 20200268874Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.Type: ApplicationFiled: March 8, 2020Publication date: August 27, 2020Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Patent number: 10596250Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.Type: GrantFiled: May 18, 2018Date of Patent: March 24, 2020Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Publication number: 20190390249Abstract: Disclosed are compositions for isolating populations of nucleic acids from biological, forensic, and environmental samples. Also disclosed are methods for using these compositions as one-step formulations for killing pathogens, inactivating nucleases, and releasing polynucleotides from other cellular components within the sample, and stabilizing the nucleic acids prior to further processing or assay. The disclosed compositions safely facilitate rapid sample collection, and provide extended storage and transport of the samples at ambient or elevated temperature without contamination of the sample or degradation of the nucleic acids contained therein. This process particularly facilitates the collection of specimens from remote locations, and under conditions previously considered hostile for preserving the integrity of nucleic acids released from lysed biological samples without the need of refrigeration or freezing prior to molecular analysis.Type: ApplicationFiled: June 19, 2017Publication date: December 26, 2019Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Publication number: 20190352378Abstract: The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.Type: ApplicationFiled: August 2, 2019Publication date: November 21, 2019Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum, Richard F. Schuman, Clara J. Sei
-
Publication number: 20190323068Abstract: The invention is directed to compositions and methods for isolating, detecting, amplifying, and quantitating pathogen-specific nucleic acids in a biological sample, and in particular PCR ready compositions that contain enzyme and are stable or long periods of time. The invention also provides diagnostic kits containing specific amplification primers, and labeled detection probes that specifically bind to the amplification products obtained therefrom. Also disclosed are compositions and methods for the isolation and characterization of nucleic acids that are specific to one or more pathogens, including for example Influenza virus and Mycobacterium tuberculosis, from a wide variety of samples including those of biological, environmental, clinical and/or veterinary origin.Type: ApplicationFiled: June 28, 2019Publication date: October 24, 2019Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Publication number: 20190323066Abstract: The invention is directed to methods, kits, compositions for the detection of microbial resistance in bacteria, viruses, parasites, fungus, and other microbes. The methods of the invention are both rapid and inexpensive thereby allowing for appropriate treatment of large numbers of individual patients.Type: ApplicationFiled: April 19, 2019Publication date: October 24, 2019Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Luke T. Daum, Gerald W. Fischer
-
Patent number: 10414819Abstract: The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response. Monoclonal antibodies produced by the non-naturally occurring antigens enhance phagocytosis and killing of mycobacteria by phagocytic cells, enhance clearance of MTB from the blood and modulate immunity and cytokine responses.Type: GrantFiled: September 26, 2016Date of Patent: September 17, 2019Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum, Richard F. Schuman, Clara J. Sei
-
Patent number: 10370437Abstract: The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.Type: GrantFiled: December 21, 2017Date of Patent: August 6, 2019Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum, Richard F. Schuman, Clara J. Sei
-
Publication number: 20190100750Abstract: The invention is directed to compositions and methods for rapidly and efficiently extracting nucleic acids and/or targeted nucleic acids sequences from biological samples. The methods of the invention comprise combining the sample with a buffer and magnetic silicon beads and concentrating the beads with a magnet or other electrical field. Liquid may be removed, or not, and an alkaline buffer is added followed by magnetic carboxy beads in a binding buffer so that nucleic acids transfer to the carboxy beads, which can be easily and quickly isolated once again with a magnet. Total nucleic acid extraction is greatly enhanced. Extracted nucleic acids can be analyzed, for example, by PCR wherein the nucleic acids can be identified and characterized. Carboxy beads may also contain a ligand so as to target specific nucleic acid sequences. The invention is also directed to kits comprising the tools and compositions for performing the methods of the invention.Type: ApplicationFiled: September 27, 2018Publication date: April 4, 2019Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Patent number: 10087439Abstract: The invention is directed to compositions and methods for rapidly and efficiently extracting nucleic acids and/or targeted nucleic acids sequences from biological samples. The methods of the invention comprise combining the sample with a buffer and magnetic silicon beads and concentrating the beads with a magnet or other electrical field. Liquid may be removed, or not, and an alkaline buffer is added followed by magnetic carboxy beads in a binding buffer so that nucleic acids transfer to the carboxy beads, which can be easily and quickly isolated once again with a magnet. Total nucleic acid extraction is greatly enhanced. Extracted nucleic acids can be analyzed, for example, by PCR wherein the nucleic acids can be identified and characterized. Carboxy beads may also contain a ligand so as to target specific nucleic acid sequences. The invention is also directed to kits comprising the tools and compositions for performing the methods of the invention.Type: GrantFiled: May 7, 2018Date of Patent: October 2, 2018Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Publication number: 20180250383Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.Type: ApplicationFiled: May 18, 2018Publication date: September 6, 2018Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Patent number: 10004799Abstract: The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection.Type: GrantFiled: March 2, 2017Date of Patent: June 26, 2018Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Patent number: 9976136Abstract: The invention is directed to compositions and methods for rapidly and efficiently extracting nucleic acids and/or targeted nucleic acids sequences from biological samples. The methods of the invention comprise combining the sample with a buffer and magnetic silicon beads and concentrating the beads with a magnet or other electrical field. Liquid may be removed, or not, and an alkaline buffer is added followed by magnetic carboxy beads in a binding buffer so that nucleic acids transfer to the carboxy beads, which can be easily and quickly isolated once again with a magnet. Total nucleic acid extraction is greatly enhanced. Extracted nucleic acids can be analyzed, for example, by PCR wherein the nucleic acids can be identified and characterized. Carboxy beads may also contain a ligand so as to target specific nucleic acid sequences. The invention is also directed to kits comprising the tools and compositions for performing the methods of the invention.Type: GrantFiled: May 12, 2016Date of Patent: May 22, 2018Assignee: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum
-
Publication number: 20180127488Abstract: The invention is directed to compositions and methods for stimulating, enhancing or modulating the immune system of a patient before or after infection by a pathogen, and in particular multidrug resistant (MDR) MTB and extremely drug resistant (XDR) MTB. Compositions of the invention contain non-naturally occurring antigens that generate an effective cellular and/or humoral immune response to MTB and/or antibodies that are specifically reactive to MTB antigens. The greater activity of the immune system generated by a vaccine of the invention increases generation of memory T cells that provide for a greater and/or extended response to an MTB infection. Responses involve an increased generation of antibodies that enhance immunity against MTB infection and promote an enhanced phagocytic response.Type: ApplicationFiled: December 21, 2017Publication date: May 10, 2018Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Luke T. Daum, Richard F. Schuman, Clara J. Sei
-
Publication number: 20180042999Abstract: The present invention is directed to compositions and methods for preventing and/or treating diseases and disorders of patients caused by non-Staphylococcal microorganisms. In particular, compositions and methods contain lysostaphin, altered forms of lysostaphin as compared to wild-type, and synergistic combinations of lysostaphin plus additional conventional treatments such as other enzyme, antibiotic and/or antibody treatment. The invention is also directed to detecting and identifying altered forms of lysostaphin that possess increased efficacy against infections as compared to wild-type lysostaphin, and forms that generate a minimal or no immune response in a patient. The invention is also directed to method of manufacturing lysostaphin and altered forms of lysostaphin, and compositions that direct the lysostaphin to the site of the infection such as aerosolized nanoparticles.Type: ApplicationFiled: October 26, 2017Publication date: February 15, 2018Applicant: Longhorn Vaccines and Diagnostics, LLCInventors: Gerald W. Fischer, Richard F. Schuman